X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC LTD with Biocon Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC LTD vs BIOCON LTD - Comparison Results

ALEMBIC LTD    Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

BIOCON LTD 
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC LTD BIOCON LTD ALEMBIC LTD/
BIOCON LTD
 
P/E (TTM) x 75.7 36.5 207.4% View Chart
P/BV x 2.8 4.9 58.0% View Chart
Dividend Yield % 0.4 1.5 26.2%  

Financials

 ALEMBIC LTD   BIOCON LTD
EQUITY SHARE DATA
    ALEMBIC LTD
Mar-16
BIOCON LTD
Mar-16
ALEMBIC LTD/
BIOCON LTD
5-Yr Chart
Click to enlarge
High Rs53496 10.7%   
Low Rs29397 7.4%   
Sales per share (Unadj.) Rs4.7174.3 2.7%  
Earnings per share (Unadj.) Rs8.844.8 19.6%  
Cash flow per share (Unadj.) Rs9.056.9 15.8%  
Dividends per share (Unadj.) Rs0.155.00 3.0%  
Dividend yield (eoy) %0.41.1 32.6%  
Book value per share (Unadj.) Rs27.7202.8 13.7%  
Shares outstanding (eoy) m267.03200.00 133.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x8.72.6 339.8%   
Avg P/E ratio x4.710.0 47.0%  
P/CF ratio (eoy) x4.67.8 58.2%  
Price / Book Value ratio x1.52.2 67.3%  
Dividend payout %1.711.2 15.3%   
Avg Mkt Cap Rs m10,96289,220 12.3%   
No. of employees `000NA4.4 0.0%   
Total wages/salary Rs m2386,363 3.7%   
Avg. sales/employee Rs ThNM7,894.5-  
Avg. wages/employee Rs ThNM1,441.2-  
Avg. net profit/employee Rs ThNM2,029.7-  
INCOME DATA
Net Sales Rs m1,26034,854 3.6%  
Other income Rs m264845 31.2%   
Total revenues Rs m1,52435,699 4.3%   
Gross profit Rs m838,200 1.0%  
Depreciation Rs m612,423 2.5%   
Interest Rs m0102 0.3%   
Profit before tax Rs m2856,520 4.4%   
Minority Interest Rs m0-744 0.0%   
Prior Period Items Rs m2,0960-   
Extraordinary Inc (Exp) Rs m-325,754 -0.6%   
Tax Rs m62,569 0.2%   
Profit after tax Rs m2,3438,961 26.1%  
Gross profit margin %6.623.5 27.9%  
Effective tax rate %2.139.4 5.4%   
Net profit margin %185.925.7 723.0%  
BALANCE SHEET DATA
Current assets Rs m1,68939,932 4.2%   
Current liabilities Rs m48616,276 3.0%   
Net working cap to sales %95.467.9 140.6%  
Current ratio x3.52.5 141.6%  
Inventory Days Days21754 405.0%  
Debtors Days Days8186 94.0%  
Net fixed assets Rs m1,62439,101 4.2%   
Share capital Rs m5341,000 53.4%   
"Free" reserves Rs m5,96038,591 15.4%   
Net worth Rs m7,40440,556 18.3%   
Long term debt Rs m10420,724 0.5%   
Total assets Rs m8,01084,816 9.4%  
Interest coverage x950.764.9 1,464.3%   
Debt to equity ratio x00.5 2.8%  
Sales to assets ratio x0.20.4 38.3%   
Return on assets %29.310.7 273.7%  
Return on equity %31.622.1 143.2%  
Return on capital %31.319.0 164.8%  
Exports to sales %2.930.7 9.6%   
Imports to sales %28.920.4 141.6%   
Exports (fob) Rs m3710,717 0.3%   
Imports (cif) Rs m3647,105 5.1%   
Fx inflow Rs m3711,789 0.3%   
Fx outflow Rs m3658,393 4.3%   
Net fx Rs m-3283,396 -9.7%   
CASH FLOW
From Operations Rs m3465,264 6.6%  
From Investments Rs m-48-9,540 0.5%  
From Financial Activity Rs m-30110,867 -2.8%  
Net Cashflow Rs m-36,591 -0.0%  

Share Holding

Indian Promoters % 64.0 40.4 158.4%  
Foreign collaborators % 0.0 20.6 -  
Indian inst/Mut Fund % 0.2 8.4 2.4%  
FIIs % 9.7 10.7 90.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.1 19.9 131.2%  
Shareholders   54,701 109,995 49.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC LTD With:   ALKEM LABORATORIES  PLETHICO PHARMA  FDC LTD.  TORRENT PHARMA  FRESENIUS KABI ONCO.  

Compare ALEMBIC LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Flat Note; Dr Reddy's & Lupin Surge over 2%(Closing)

Indian share markets continued to trade just above the dotted line in the afternoon session in a lackluster day of trading. At the closing bell, the BSE Sensex closed higher by 33 points.

Related Views on News

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Biocon: High Other Income And Licensing Income Drive Growth (Quarterly Results Update - Detailed)

Nov 7, 2016

Biocon has announced its 2QFY17. The company has reported 19.8% YoY growth in net sales and profits of Rs 1.5 bn for the quarter. Here is our analysis of the results.

Biocon: Lower R&D Expenses Help Margin Expansion (Quarterly Results Update - Detailed)

Sep 19, 2016

Biocon has announced its 1QFY17. The company has reported 21.1% YoY growth in total income and 34.6% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC LTD SHARE PRICE


Aug 22, 2017 (Close)

TRACK ALEMBIC LTD

  • Track your investment in ALEMBIC LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ALEMBIC LTD - UNICHEM LAB COMPARISON

COMPARE ALEMBIC LTD WITH

MARKET STATS